Currently, the National Institute of Health (NIH) guidelines do not recommend the use of low-titer CP for hospitalized patients with COVID-19 of any stage and permit high-titer CP use only in hospitalized patients with evidence of impaired immunity or in the context of a clinical trial [96]. The gene discussed is CP; the disease is COVID-19.